title: Bacteriophages displaying anticancer peptides in combined antibacterial and anticancer treatment.
abstract: OBJECTIVE
  Novel anticancer strategies have employed bacteriophages as drug carriers and display platforms for anticancer agents; however, bacteriophage-based platforms maintain their natural antibacterial activity. This study provides the assessment of combined anticancer (engineered) and antibacterial (natural) phage activity in therapies.
  
  
  METHODS
  An in vivo BALB/c mouse model of 4T1 tumor growth accompanied by surgical wound infection was applied. The wounds were located in the areas of tumors. Bacteriophages (T4) were modified with anticancer Tyr-Ile-Gly-Ser-Arg (YIGSR) peptides by phage display and injected intraperitoneally.
  
  
  CONCLUSIONS
  Tumor growth was decreased in mice treated with YIGSR-displaying phages. The acuteness of wounds, bacterial load and inflammatory markers in phages-treated mice were markedly decreased. Thus, engineered bacteriophages combine antibacterial and anticancer activity.
authors.affiliation: Institute of Immunology & Experimental Therapy, Polish Academy of Sciences, Weigla 12, 53-114 Wrocław, Poland.
authors.forename: Krystyna
authors.initials: K
authors.lastname: Dąbrowska
authors.forename: Zuzanna
authors.initials: Z
authors.lastname: Kaźmierczak
authors.forename: Joanna
authors.initials: J
authors.lastname: Majewska
authors.forename: Paulina
authors.initials: P
authors.lastname: Miernikiewicz
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Piotrowicz
authors.forename: Joanna
authors.initials: J
authors.lastname: Wietrzyk
authors.forename: Dorota
authors.initials: D
authors.lastname: Lecion
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Hodyra
authors.forename: Anna
authors.initials: A
authors.lastname: Nasulewicz-Goldeman
authors.forename: Barbara
authors.initials: B
authors.lastname: Owczarek
authors.forename: Andrzej
authors.initials: A
authors.lastname: Górski
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000378:metabolism; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000378:metabolism; D001424:Bacterial Infections / Q000628:therapy*; D017122:Bacteriophage T4 / Q000235:genetics* / Q000378:metabolism; D001691:Biological Therapy; D016503:Drug Delivery Systems / Q000379:methods*; D004926:Escherichia coli / Q000821:virology; D005260:Female; D015870:Gene Expression; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D009369:Neoplasms / Q000188:drug therapy*; D010455:Peptides / Q000008:administration & dosage* / Q000235:genetics* / Q000378:metabolism
chemical_list: D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D010455:Peptides
keywords: T4 phage; antibacterial; anticancer; infection; phage display; wound